FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115232902> ?p ?o ?g. }

• W2115232902 endingPage "983" @default.
• W2115232902 startingPage "978" @default.
• W2115232902 abstract "Seventy-seven patients (age 12 to 46 years) who underwent allogeneic marrow transplantation for hematologic malignancy or aplastic anemia and who had grade II to IV acute graft-versus-host disease despite methotrexate prophylaxis were randomly assigned to receive methylprednisolone 2 mg/kg per day intravenously (n = 39) or cyclosporine (n = 38) either 12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously. In both groups, clinical and histologic evidence of graft-versus-host disease was detected at medians of 16 and 25 days, respectively. Drugs were given for a minimum of 14 days unless significant deterioration occurred. If graft-versus-host disease did not improve with this therapy, treatment with a second agent was initiated. Treatment responses were scored after reviewing clinical and laboratory data collected before, during, and after the 14-day treatment period. Possible scores were as follows: -1, worse; 0, no change; + 1, improvement in one organ system (skin, liver, gut) with no deterioration in the other two; +2, complete resolution of all involved systems. The median response score among 39 methylprednisolone-treated patients was 0. Sixteen patients (41 percent) showed response to treatment, 11 with partial and five with complete response. The median response score among 38 cyclosporine-treated patients was +1. Twenty-three patients (61 percent) showed response to treatment, 15 with partial and eight with complete response (p = 0.039). Twenty patients receiving methylprednisolone and 18 receiving cyclosporine required additional therapy. The incidence of chronic graft-versus-host disease was similar in both groups. It developed in all nonresponding patients at risk who had received secondary therapy. Among responding patients (scores +1 or +2) who were not given additional treatment, chronic graft-versus-host disease developed in eight of 11 (72 percent) receiving methylprednisolone and five of ten (50 percent) receiving cyclosporine. Survival beyond 17 months was similar in the two groups (28 percent and 24 percent, respectively). These data suggest that cyclosporine is a useful agent for the treatment of acute graft-versus-host disease, comparable in its efficacy to methylprednisolone." @default.
• W2115232902 created "2016-06-24" @default.
• W2115232902 creator A5003452358 @default.
• W2115232902 creator A5032503509 @default.
• W2115232902 creator A5037247107 @default.
• W2115232902 creator A5051266970 @default.
• W2115232902 creator A5053986124 @default.
• W2115232902 creator A5056405520 @default.
• W2115232902 creator A5059063645 @default.
• W2115232902 creator A5059666930 @default.
• W2115232902 creator A5062054752 @default.
• W2115232902 creator A5070624070 @default.
• W2115232902 creator A5085787488 @default.
• W2115232902 creator A5089314070 @default.
• W2115232902 creator A5089494498 @default.
• W2115232902 date "1985-06-01" @default.
• W2115232902 modified "2023-10-16" @default.
• W2115232902 title "Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine" @default.
• W2115232902 cites W1562876511 @default.
• W2115232902 cites W193514409 @default.
• W2115232902 cites W1964099284 @default.
• W2115232902 cites W1971697324 @default.
• W2115232902 cites W1977790681 @default.
• W2115232902 cites W1991972231 @default.
• W2115232902 cites W2008201186 @default.
• W2115232902 cites W2023497948 @default.
• W2115232902 cites W2034136287 @default.
• W2115232902 cites W2084886561 @default.
• W2115232902 cites W2088337552 @default.
• W2115232902 cites W2105506999 @default.
• W2115232902 cites W2123534743 @default.
• W2115232902 cites W2173629810 @default.
• W2115232902 cites W33772365 @default.
• W2115232902 cites W5387557 @default.
• W2115232902 cites W95192746 @default.
• W2115232902 doi "https://doi.org/10.1016/0002-9343(85)90221-9" @default.
• W2115232902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3893112" @default.
• W2115232902 hasPublicationYear "1985" @default.
• W2115232902 type Work @default.
• W2115232902 sameAs 2115232902 @default.
• W2115232902 citedByCount "72" @default.
• W2115232902 countsByYear W21152329022013 @default.
• W2115232902 countsByYear W21152329022014 @default.
• W2115232902 countsByYear W21152329022016 @default.
• W2115232902 countsByYear W21152329022019 @default.
• W2115232902 countsByYear W21152329022020 @default.
• W2115232902 countsByYear W21152329022021 @default.
• W2115232902 countsByYear W21152329022022 @default.
• W2115232902 crossrefType "journal-article" @default.
• W2115232902 hasAuthorship W2115232902A5003452358 @default.
• W2115232902 hasAuthorship W2115232902A5032503509 @default.
• W2115232902 hasAuthorship W2115232902A5037247107 @default.
• W2115232902 hasAuthorship W2115232902A5051266970 @default.
• W2115232902 hasAuthorship W2115232902A5053986124 @default.
• W2115232902 hasAuthorship W2115232902A5056405520 @default.
• W2115232902 hasAuthorship W2115232902A5059063645 @default.
• W2115232902 hasAuthorship W2115232902A5059666930 @default.
• W2115232902 hasAuthorship W2115232902A5062054752 @default.
• W2115232902 hasAuthorship W2115232902A5070624070 @default.
• W2115232902 hasAuthorship W2115232902A5085787488 @default.
• W2115232902 hasAuthorship W2115232902A5089314070 @default.
• W2115232902 hasAuthorship W2115232902A5089494498 @default.
• W2115232902 hasConcept C120665830 @default.
• W2115232902 hasConcept C121332964 @default.
• W2115232902 hasConcept C126322002 @default.
• W2115232902 hasConcept C141071460 @default.
• W2115232902 hasConcept C2776804153 @default.
• W2115232902 hasConcept C2779972918 @default.
• W2115232902 hasConcept C2780007613 @default.
• W2115232902 hasConcept C2780372218 @default.
• W2115232902 hasConcept C2781059491 @default.
• W2115232902 hasConcept C2781440808 @default.
• W2115232902 hasConcept C2911091166 @default.
• W2115232902 hasConcept C61511704 @default.
• W2115232902 hasConcept C71924100 @default.
• W2115232902 hasConcept C90924648 @default.
• W2115232902 hasConceptScore W2115232902C120665830 @default.
• W2115232902 hasConceptScore W2115232902C121332964 @default.
• W2115232902 hasConceptScore W2115232902C126322002 @default.
• W2115232902 hasConceptScore W2115232902C141071460 @default.
• W2115232902 hasConceptScore W2115232902C2776804153 @default.
• W2115232902 hasConceptScore W2115232902C2779972918 @default.
• W2115232902 hasConceptScore W2115232902C2780007613 @default.
• W2115232902 hasConceptScore W2115232902C2780372218 @default.
• W2115232902 hasConceptScore W2115232902C2781059491 @default.
• W2115232902 hasConceptScore W2115232902C2781440808 @default.
• W2115232902 hasConceptScore W2115232902C2911091166 @default.
• W2115232902 hasConceptScore W2115232902C61511704 @default.
• W2115232902 hasConceptScore W2115232902C71924100 @default.
• W2115232902 hasConceptScore W2115232902C90924648 @default.
• W2115232902 hasIssue "6" @default.
• W2115232902 hasLocation W21152329021 @default.
• W2115232902 hasLocation W21152329022 @default.
• W2115232902 hasOpenAccess W2115232902 @default.
• W2115232902 hasPrimaryLocation W21152329021 @default.
• W2115232902 hasRelatedWork W2161913883 @default.
• W2115232902 hasRelatedWork W2388870263 @default.
• W2115232902 hasRelatedWork W2406718099 @default.

• next